Skip to main content

Table 1 Data describing study design, population and setting

From: A systematic review of the sensitivity and specificity of lateral flow devices in the detection of SARS-CoV-2

Study Month and year of publication Origin Sample size Gender = Female Gender = Male Mean Age Population Setting—Dichotomise Sample collection (who collected it and when) Intervention (which LFD)
Abdelrazik et al. [12] December 2020 Egypt 310 126 184 42.0 Confirmed, contacts and exposed healthcare professionals Primary Healthcare Facility/Hospital N/A BIOCREDIT
Abdulrahman et al. [13] December 2020 Bahrain 4183 1820 2363 30.9 Mildly symptomatic COVID-19 Testing Site Trained healthcare professionals Panbio
Albert et al. [14] November 2020 Spain 412 239 173 31.0 Symptomatic Primary Healthcare Facility/Hospital Trained healthcare professionals Panbio
Berger et al. [15] November 2020 Geneva, Switzerland 529 285 244 34.9 Symptoms/contact COVID-19 Testing Site Trained healthcare professionals Panbio; STANDARD Q
Blairon et al. [16] August 2020 Belgium 774 N/A N/A N/A N/A Primary Healthcare Facility/Hospital N/A Coris
Bulilete et al. [17] November 2020 Mallorca, Spain 1369 743 626 42.5 Symptoms/contact COVID-19 Testing Site Trained healthcare professionals Panbio
Cerutti et al. [18] September 2020 Italy 330 134 196 44.6 Symptomatic/high-risk travel N/A N/A STANDARD Q
Chaimayo et al. [19] November 2020 Thailand 454 231 223 40.4 Symptomatic Primary Healthcare Facility/Hospital N/A STANDARD Q
Courtellemont et al. [20] October 2020 France 248 131 117 43.0 Asymptomatic and symptomatic Primary Healthcare Facility/Hospital Trained personnel COVID-VIRO
Drevinek et al. [21] November 2020 Czech Republic 591 327 246 40.0 Symptoms/contact Primary Healthcare Facility/Hospital N.A Panbio; STANDARD Q
Gremmels et al. [22] October 2020 Netherlands 1575 844 523 36.4 Symptomatic Primary Healthcare Facility/Hospital N/A Panbio
Iglὁi et al. [23] November 2020 Rotterdam, Netherlands 970 776 194 53.0 Symptomatic COVID-19 Testing Site Trained personnel STANDARD Q
L.J. Krüger et al. (2020) [24] December 2020 Heidelberg and Berlin, Germany 1108 78 1030 39.4 Symptoms/contact COVID-19 Testing Site Trained personnel Panbio
L.J. Krüger et al. (2020) [25] October 2020 Berlin and Heidelberg, Germany. Liverpool, UK 2417 1276 1140 40.4 Symptoms/contact Both N/A Bioeasy, Coris, STANDARD Q
Linares et al. [26] October 2020 Madrid, Spain 255 148 107 46.4 Symptoms/contact (ER), both asymptomatic and symptomatic (72.1%) in PH Primary Healthcare Facility/Hospital N/A Panbio
Masiá et al. [27] November 2020 Alicante, Spain 913 490 423 40.6 Symptoms/contact Primary Healthcare Facility/Hospital Trained healthcare professionals Panbio
Merino-Amador et al. [28] November 2020 Madrid and Basque Country, Spain 958 587 370 42.4 Symptoms/contact Primary Healthcare Facility/Hospital Trained healthcare professionals Panbio
Moeren et al. [29] October 2020 Netherlands 352 N/A N/A N/A Symptomatic COVID-19 Testing Site Trained personnel BD Veritor
Nalumansi et al. [30] October 2020 Uganda 262 29 233 34.0 N/A Primary Healthcare Facility/Hospital Laboratory personnel STANDARD Q
Peto et al. [31] January 2021 Multiple sites across the UK 6954 N/A N/A N/A RT-PCR-confirmed diagnosis of SARS-CoV-2 infection within 5 days of the original PCR result Both Self-test Innova
Porte et al. [32] October 2020 Santiago, Chile 127 59 68 38.0 Symptoms/contact Primary Healthcare Facility/Hospital Trained personnel Bioeasy
Schwob et al. [33] November 2020 Lausanne, Switzerland 928 455 473 31.0 symptomatic COVID-19 Testing Site NP = health professional, saliva = self STANDARD Q; Panbio; COVID-VIRO
Torres et al. [34] December 2020 Spain 634 355 279 37.0 Asymptomatic contacts Primary Healthcare Facility/Hospital Trained healthcare professionals Panbio
Veyrenche et al. [35] September 2020 Montpellier, France 65 N/A N/A N/A Asymptomatic and symptomatic Primary Healthcare Facility/Hospital N/A Coris